Nuvation Bio Inc expected to post a loss of 16 cents a share - Earnings Preview

Nuvation Bio

06/05/2025 24:10

Nuvation Bio Inc NUVB.N, NUVB.K is expected to show a rise in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The San Francisco California-based  company is expected to report revenue of $416.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Nuvation Bio Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Nuvation Bio Inc is $8.00‚Äč, above‚Äč its last closing price of $2.38. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.14
-0.14
-0.15
Missed
-8.7
Sep. 30 2024
-0.12
-0.13
-0.15
Missed
-15.4
Jun. 30 2024
-0.06
-0.06
-0.15
Missed
-156.4‚Äč
Mar. 31 2024
-0.09
-0.10
-0.07
Beat
26.9
‚Äč‚ÄčDec. 31 2023
-0.09
-0.10
-0.06
Beat
42.8
Sep. 30 2023
-0.11
-0.11
-0.09
Beat
17.9‚Äč
Jun. 30 2023
-0.11
-0.11
-0.09
Beat
19.5
Mar. 31 2023
-0.10
-0.10
-0.10
Met
0

This summary was machine generated May 5 at 23:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)